Long-acting formulation of a new muscarinic receptor antagonist for the treatment of overactive bladder

By Teng Lesheng   Jiang Chaojun   Sun Fengying   Li Chunmei   Teng Lirong   Meng Qingfan   Lee Robert J.   Li Youxin  

Journal of Microencapsulation, Vol. 30, Iss. 2, 2013-03 ,pp. : 116-123

Informa Healthcare

Access to resources Recommend Favorite

The efficacy and tolerability of tarafenacin, a new muscarinic acetylcholine receptor M3 antagonist in patients with overactive bladder; randomised, double‐blind, placebo‐controlled phase 2 study

By  

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (ELECTRONIC), Vol. 69, Iss. 2, 2015-02 ,pp. : 242-250

John Wiley & Sons Inc

Access to resources Recommend Favorite

Darifenacin treatment of patients ≥ 65 years with overactive bladder: results of a randomized, controlled, 12-week trial

By Chapple C   DuBeau C   Ebinger U   Rekeda L   Viegas A  

Current Medical Research and Opinion, Vol. 23, Iss. 10, 2007-10 ,pp. : 2347-2358

Informa Healthcare

Access to resources Recommend Favorite

Long-term darifenacin treatment for overactive bladder in patients aged 65 years and older: analysis of results from a 2-year, open-label extension study

By Hill Simon   Elhilali Mostafa   Millard Richard J   Dwyer Peter L   Lheritier Karine   Kawakami Fernando T.   Steel Michael  

Current Medical Research and Opinion, Vol. 23, Iss. 11, 2007-11 ,pp. : 2697-2704

Informa Healthcare

Access to resources Recommend Favorite

Quantitative Analysis of the Levels of Expression of Muscarinic Receptor Subtype RNA in the Detrusor Muscle of Patients with Overactive Bladder

By Hinata N.  

Molecular Diagnosis, Vol. 8, Iss. 1, 2004-01 ,pp. : 17-22

Adis International

Access to resources Recommend Favorite